Small Molecule CDMO Market Size, Share & Industry Analysis, By Service Type (Drug Substance Services [Development & Analytical and API Manufacturing], Drug Product Services [Formulation & Analytical Development and Manufacturing], and Packaging & Supply Services), By Product Type (Active Pharmaceutical Ingredients and Finished Drug Products), By Molecule Status (New Chemical Entities and Generics), By Application (Oncology, Cardiovascular Diseases, and Neurological Diseases), By End User (Pharmaceutical Companies and Biopharmaceutical Companies), and Regional Forecast for 2026 to 2034

The small molecule CDMO market size was valued at USD 77.61 billion in 2025 and is projected to grow from USD 83.21 billion in 2026 to USD 142.24 billion by 2034, exhibiting a CAGR of 6.9% during the forecast period.

Small molecule CDMO refers to an outsourced partner that develops and produces conventional chemical drugs, including pills and capsules, for pharmaceutical and biotech companies. The growing prevalence of chronic conditions, expansion of small molecule pipelines, and increasing outsourcing by pharmaceutical and biotechnological companies are resulting in an enhanced adoption rate of these small molecule manufacturing services in the market. The expansion of Contract Development and Manufacturing Organizations (CDMOs) is further augmenting the adoption of small molecule CDMOs in the market.

• For instance, according to the 2026 data published by the American Cancer Society, approximately 2.0 million new cancer cases were estimated in the U.S.

Furthermore, the growing focus on improving their service capabilities among companies, including Thermo Fisher Scientific Inc. and Lonza, among others, is contributing to the demand for these services in the market.

Small Molecule CDMO Market Trends

Increasing Adoption of Digital Tools and Artificial Intelligence is Emerging Market Trend

The increasing utilization of digital technologies and artificial intelligence is emerging as a major trend in the global market. Small molecule development and manufacturing involve large volumes of experimental, process, analytical, and quality data, including ingredient compatibility, among others. The CDMOs are increasingly deploying machine learning and automated process-modelling platforms to analyze these datasets and improve development and manufacturing decisions more rapidly.

Additionally, AI tools supports reaction-condition optimization, synthetic-route evaluation, impurity prediction, solid-form selection and formulation screening further helping CDMO in reducing the number of physical experiments required. These solutions also detect process risks earlier and accelerate the transition of small-molecule candidates from laboratory development to clinical manufacturing, resulting in an increasing adoption of outsourcing services among pharmaceutical and biopharmaceutical companies in the market.

• For instance, according to 2024 data published by the Food and Drug Administration (FDA), it was reported that about 300 regulatory applications with artificial intelligence components were received from 2016 to 2021.

Market Dynamics

Market Drivers

Download Free sample to learn more about this report.

Growing Prevalence of Chronic Disorders to Drive Market Growth

The increasing prevalence of chronic conditions, including cardiovascular conditions, cancer, neurological diseases, and others, is resulting in the growing demand for novel and effective molecules for various therapeutic areas. Increasing demand for these molecules is further augmenting the outsourcing of drug development services to CDMOs among pharmaceutical and biopharmaceutical companies, including analytical and testing services, product development services, and others in the market.

• For instance, according to 2026 data published by the Parkinson’s Foundation, about 1.1 million people are affected by Parkinson’s disease in the U.S.

This, along with a growing demand for generics and expansion of biotechnology and pharmaceutical companies, is boosting small molecule CDMO market growth. Moreover, the growing focus of major companies on offering novel services, are also expected to drive the adoption of these services.

Market Restraints

High Cost Associated with Advanced Manufacturing and Infrastructure to Limit Market Growth

The significant investment required to establish the specialized manufacturing and testing infrastructure is anticipated to hamper the market. Small-molecule development and manufacturing facilities require specialized reactors, purification systems, analytical laboratories, cleanrooms, solvent-handling systems, process-control technologies, and validated quality-management infrastructure. These investments become substantially higher when facilities must accommodate highly potent active pharmaceutical ingredients, controlled substances, complex multistep chemistry, or advanced particle-engineering processes.

This, along with advanced analytical and performance-testing laboratories, requires advanced systems for these services, which subsequently increases the overall investment, further making it challenging for smaller CDMOs to adopt these equipment, thereby hindering market growth.

Market Opportunities

Expansion of CDMO Across Developing Nations to Create Lucrative Opportunities

The expansion of CDMO organizations across developing nations presents a major opportunity for the market. There is a growing development of CDMO settings, advanced laboratory networks, and research facilities across countries including India, Brazil, and others. Additionally, growing healthcare expenditure, expanding pharma and biotech pipelines, and increasing government inorganic growth strategies contribute to innovation and contributing to the demand for outsourced services worldwide.

• According to 2023 data published by the World Bank Group, India spends 3.34% of its GDP on healthcare.

Market Challenges

Limited Number of CDMOs in Emerging Countries to Hamper the Market Growth

The limited presence of well-developed CDMOs in various developing countries is a key challenge for the market expansion. Although emerging countries offer advantages including a large patient population base and reduced overall operating costs, many countries still lack a developed ecosystem of specialized CDMOs with advanced capabilities in clinical and commercial manufacturing services, among others. Therefore, the limited number of well-established CDMOs in developing nations may limit the adoption of outsourcing services, thereby hampering the growth of the market.

SEGMENTATION ANALYSIS

By Service Type

Increasing Approval of Drugs Led to the Drug Substance Services Segmental Dominance

Based on the service type, the market is divided into drug substance services, drug product services, and packaging and supply services. Drug substance services are further classified into drug substance development & analytical services and clinical & commercial API manufacturing services. Drug product services are divided into formulation, process & analytical development and clinical & commercial drug product manufacturing. Packaging and supply services are divided into packaging & labeling and storage & distribution.

To know how our report can help streamline your business, Speak to Analyst

The drug substance services segment held the largest small molecule CDMO market share in 2025. The growth is due to growing demand for novel drugs and increasing number of drug approvals, resulting in increasing adoption of drug substance services, including drug substance manufacturing services, and others among pharmaceutical and biopharmaceutical companies. This, coupled with growing prescription of generics, is further anticipated to contribute to the segment growth.

• For instance, according to 2024 statistics published by the Food and Drug Administration (FDA), about 50 novel drugs were approved by Center for Drug Evaluation and Research (CDER) in the U.S.

The drug product services segment is expected to grow at a CAGR of 6.8% over the forecast period.

By Product Type

Growing Approval for Small Molecules Led to Dominance of Finished Drug Products Segment

Based on the product type, the market is segmented into Active Pharmaceutical Ingredients (API) and finished drug products.

The finished drug products segment dominated the global market in 2025. The growth is owing to rising demand for small-molecule drugs, resulting in growing approval for these products. This, along with increasing partnerships for outsourcing services with CDMOs, growing technological advancements, among others are some of the additional factors contributing to the segmental growth in the market.

• For instance, according to the 2024 statistics published by the American Chemical Society (ACS), it was reported that the approved 28 small-molecule drugs account for about 56% of new drugs in the U.S.

The Active Pharmaceutical Ingredients (API) segment is set to flourish with a growth rate of 6.8% during the forecast period.

By Molecule Status

Increasing Service Requirements Led to the Dominance of the New Chemical Entities Segment

Based on molecule status, the market is bifurcated into new chemical entities and generics.

The new chemical entities segment dominated the global market in 2025. The growth is due to increasing prevalence of chronic conditions and growing requirement of extensive services including synthetic-route design, medicinal and process chemistry, impurity identification, analytical-method development, and others, resulting in a rising adoption of outsourcing services for new chemical entities.

The generics segment is set to grow at a CAGR of 6.8% during the forecast period.

By Application

Growing Prevalence of Cancer Led to the Oncology Segmental Dominance

Based on application, the market is segmented into oncology, cardiovascular diseases, neurological diseases, and others.

The oncology segment dominated the market in 2025. The growing prevalence of cancer, growing adoption of outsourcing services, and rising number of CDMOs, among others, are some of the key factors contributing to the growth of the segment in the market. Furthermore, the segment is set to hold a 35.4% share in 2026.

• For instance, according to 2023 data published by Cancer Research U.K., around 403,000 people get diagnosed with cancer each year in the U.K.

In addition, neurological diseases are projected to grow at a 7.3% CAGR during the forecast period.

By End User

Increasing Number of Pharmaceutical Companies Led to the Segmental Dominance

Based on end user, the market is divided into pharmaceutical companies, biopharmaceutical companies, and others.

The pharmaceutical companies segment dominated the market in 2025. The increasing demand for innovative drugs and the increasing number of pharmaceutical companies, among others, are some of the crucial factors contributing to the segment growth. Furthermore, the segment is set to hold a 59.9% share in 2026.

• For instance, according to 2026 data published by Cross River Therapy (CRT), there are approximately 5,000 companies in the U.S.

In addition, biopharmaceutical companies are projected to grow at a 7.3% CAGR during the forecast period.

Small Molecule CDMO Market Regional Outlook

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

The North America market held the dominant share in 2024, valued at USD 27.35 billion, and also took the leading share in 2025 with USD 29.19 billion. The growing prevalence of chronic diseases, increasing adoption of outsourcing services, increasing healthcare spending and adoption of digital tools, among others, are some of the crucial factors contributing to the regional market growth.

• For instance, according to 2024 data published by the Centers for Medicare & Medicaid Services (CMS), the healthcare expenditure is USD 5.3 trillion in the U.S.

U.S. Small Molecule CDMO Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 26.98 billion in 2026, accounting for roughly 32.4% of global sales.

Europe

Europe is projected to record a growth rate of 6.1% over the forecast period, which is the second highest among all regions, and reach a valuation of USD 23.24 billion by 2026. The increasing pharmaceutical CDMO services are likely to contribute to the market growth.

U.K. Small Molecule CDMO Market

The U.K. market in 2026 is estimated at around USD 4.09 billion, representing roughly 4.9% of global revenues.

Germany Small Molecule CDMO Market

Germany’s market is projected to reach approximately USD 5.10 billion in 2026, equivalent to around 6.1% of global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 21.19 billion in 2026 and secure the position of the third-largest region in the market. The increase in outsourcing of custom pharmaceutical manufacturing services and expansion of drug pipelines are likely to contribute to the market growth.

Japan Small Molecule CDMO Market

The Japan market in 2026 is estimated at around USD 4.08 billion, accounting for roughly 4.9% of global revenues. Japan is expected to grow due to the growing number of CDMOs in the market.

China Small Molecule CDMO Market

China’s market is projected to be one of the largest worldwide, with 2026 revenues estimated at around USD 7.16 billion, representing roughly 8.6% of global sales.

India Small Molecule CDMO Market

The India market size in 2026 is estimated at around USD 3.39 billion, accounting for roughly 4.1% of global revenues.

Latin America and Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness moderate growth in this market space during the forecast period. The Latin America market is set to reach a valuation of USD 4.25 billion in 2026.  The increasing focus on pharmaceutical process development and the growing adoption of commercial pharmaceutical manufacturing services are resulting in market growth in the region. The Middle East & Africa is also anticipated to grow due to the increasing pharmaceutical outsourcing services and increasing small molecule drug development among the key service providers in the market. In the Middle East & Africa, the GCC is set to reach a value of USD 0.75 billion in 2026.

South Africa Small Molecule CDMO Market

The South Africa market is projected to reach around USD 0.54 billion in 2026, representing roughly 0.6% of global revenues.

Competitive Landscape

Key Industry Players

Increasing Key Player’s Focus toward Expansion Strategies to Support Market Competition

A robust services portfolio, along with a significant emphasis on inorganic strategies globally, is one of the key factors contributing to the dominance of key companies in the market. Thermo Fisher Scientific Inc., and Lonza were the major companies in the market in 2025. Moreover, the growing focus of key companies on expansion strategies is likely to strengthen their brand presence.

• For instance, in February 2021, Lonza expanded solid form services for small molecule drugs with an aim to strengthen its presence in the market.

CordenPharma and others, are also growing in the market, primarily due to their increasing focus on the provision of novel service offerings in the market.

List of Key Small Molecule CDMO Companies Profiled

• Lonza (Switzerland)
• Thermo Fisher Scientific Inc. (U.S.)
• Recipharm AB (Sweden)
• Catalent, Inc. (U.S.)
• Siegfried Holding AG (Switzerland)
• Cambrex Corporation (U.S.)
• CordenPharma (Switzerland)
• Curia Global, Inc. (U.S.)
• Piramal Pharma Solutions (India)

KEY INDUSTRY DEVELOPMENTS

• June 2026: Siegfried Holding AG opened its new large-scale production facility for API manufacturing in Minden, Germany.
• March 2026: Cambrex Corporation announced the completion of initial engineering studies for its new, large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles City, Iowa.
• March 2026: Axplora announced a major milestone in its USD 60.0 million investment program at its Farmabios site in Gropello Cairoli.
• January 2026: Siegfried, a global CDMO for the pharmaceutical industry, signed binding agreements with an affiliate of SK Capital Partners to acquire the drug substance business of the Noramco Group and Extractas Bioscience.
• October 2025: Curia Global, Inc., a global research, development and manufacturing organization, completed a USD 4.0 million investment to upgrade its two API aseptic suites in Valladolid, Spain.

REPORT COVERAGE

The report provides a detailed small molecule CDMO market analysis and focuses on key aspects such as leading companies and market segmentation, including service type, product type, molecule status, application, and end user. Besides this, the global report offers insights into the market growth trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth and advancement of the market over recent years.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation